Lopressor/use in specific populations: Difference between revisions

Jump to navigation Jump to search
← Older edit
VisualWikitext
Gerald Chi (talk | contribs)
CMEAdmin, Bureaucrats, bureaucrats, editnews, exportpages, interwiki, nocaptcha, nukepages, smwadministrator, Administrators, Widget editors
17,702 edits
mNo edit summary
GeraldChi (talk | contribs)
Bureaucrats, bureaucrats, nocaptcha, Administrators
8,887 edits
 
(7 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
#REDIRECT [[Metoprolol tartrate#Use in Specific Populations]]
{{Metoprolol}}
{{CMG}}
 
==Use in Specific Populations==
===={{pcat}} C====
Upon confirming the diagnosis of pregnancy, women should immediately inform the doctor.
Lopressor has been shown to increase postimplantation loss and decrease neonatal survival in rats at doses up to 11 times the maximum daily human dose of 450 mg, when based on surface area. Distribution studies in mice confirm exposure of the fetus when Lopressor is administered to the pregnant animal. These limited animal studies do not indicate direct or indirect harmful effects with respect to teratogenicity (see Carcinogenesis, Mutagenesis, Impairment of Fertility).
There are no adequate and well-controlled studies in pregnant women. The amount of data on the use of metoprolol in pregnant women is limited. The risk to the fetus/mother is unknown. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
====Nursing Mothers====
Lopressor is excreted in breast milk in a very small quantity. An infant consuming 1 liter of breast milk daily would receive a dose of less than 1 mg of the drug.
 
====Fertility====
The effects of Lopressor on the fertility of humans have not been studied.
Lopressor showed effects on spermatogenesis in male rats at a therapeutic dose level, but had no effect on rates of conception at higher doses in animal fertility studies (see Carcinogenesis, Mutagenesis, Impairment of Fertility).
====Pediatric Use====
Safety and effectiveness in pediatric patients have not been established.
 
====Geriatric Use====
Clinical trials of Lopressor in hypertension did not include sufficient numbers of elderly patients to determine whether patients over 65 years of age differ from younger subjects in their response to Lopressor. Other reported clinical experience in elderly hypertensive patients has not identified any difference in response from younger patients.
In worldwide clinical trials of Lopressor in myocardial infarction, where approximately 478 patients were over 65 years of age (0 over 75 years of age), no age-related differences in safety and effectiveness were found. Other reported clinical experience in myocardial infarction has not identified differences in response between the elderly and younger patients. However, greater sensitivity of some elderly individuals taking Lopressor cannot be categorically ruled out. Therefore, in general, it is recommended that dosing proceed with caution in this population.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = LOPRESSOR (METOPROLOL TARTRATE) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb05420c-fd24-4672-9f62-fdd313819287 | publisher =  | date =  | accessdate = }}</ref>
 
==References==
 
{{Reflist}}
 
{{FDA}}
 
[[Category:Drugs]]
[[Category:Cardiovascular Drugs]]
[[Category:Beta blockers]]

Latest revision as of 03:51, 22 July 2014

Redirect to:

Retrieved from "https://www.wikidoc.org/index.php?title=Lopressor/use_in_specific_populations&oldid=998886"